参麦及灯盏花联合治疗非ST段抬高性心肌梗死临床观察.docVIP

参麦及灯盏花联合治疗非ST段抬高性心肌梗死临床观察[摘要]目的 探讨中西医结合治疗非ST段抬高性心肌梗死(NSTEAMI)的有效性和安全性。方法 将56例确诊为NSTEAMI的患者,随机分为受试组和对照组各28例,对照组给予低分子肝素、氯吡格雷、阿司匹林和其他基础治疗,受试组在此基础上给予参麦和灯盏花。观察比较两组用药后1周、1个月主要不良心脏事件和不良反应发生情况。结果 受试组终点事件和主要不良心脏事件较对照组减少( P＜ 0.05 )。结论 在西医基础上联用参麦和灯盏花治疗NSTEAMI安全有效。 [关键词] 非ST段抬高性心肌梗死 ；参麦 ；灯盏花 [中图分类号]R544.2+2 [文献标识码] B[文章编号]1673-9701（2011） 27-66-02 Effects of Combination of Shenmai and Erigeron Breviscapus in Treatmentof Patients with non-ST Segment Elevation Acute Myocardium Infarction ZHANGPing Department of Cardiology, Zhangzhou City People’s Hospital in Fujian Province, Zhangzhou,363000,China [Abstract] Objective To investigate the efficacy and safety of integrated chinese traditional and western medicine therapy innon-ST-segment elevation acute myocardial infarction（NSTEAMI）. Methods Fifty-six patients with NSTEAMI were randomly and equally divided into treatment group which received shenmai and Erigeron Breviscapus combined with low-molecula-weight heparin, aspirin and clopidogrel and other therapy, and the control group which received placebo combined with the same therapy. The changes of the main adverse cardiovascular events（MACE）were observed after 7 days, 1 month, and adverse drug effect were observed. ResultsCompared with those of the control group, the patients in treatmeant group showed the endpoint events and MACE incidence decreased （P ＜0.05）There were no serious adverse drug effects. Conclusion Shenmai and Erigeron Breviscapus combined with routine therapy is effective and safe in the treatment of NESTEAMI. [Key words]Non-ST-segment elevation acute myocardial infarction；Shenmai；Erigeron breviscapus 急性心肌梗死是一种严重危害人类健康的疾病，致残、致死率高。目前西医采用急诊介入治疗，使该病的预后明显改善，但因患者的个体差异、经济条件和基层医院的技术条件所限，不能得到相应的治疗。本研究根据当地的实际情况，对NSTEAMI患者采用中西医结合治疗，取得较满意疗效，报道如下。 1资料与方法 1.1一般资料 选择2004年3月～2009年12月我院内科住院急性NSTEAMI患者56例，符合NSTEAM I诊断[1]，排除药物过敏及有抗凝治疗禁忌证者。将患者按就诊顺序采用双盲、随机、平行对照试验原则，分为对照组和受试组各28例。对照组男14例，女14例，年龄（63. 6±9.5）岁；受试组男15例，女13例，年龄(64.0±9.6)岁。所有患者能够完成整个实验，两组性别、年龄